Summary of Novanta Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Revenue: $250 million, representing a 9% increase year-over-year.

Organic Growth: 2% in Q4, with 4% sequential growth.

Bookings: Increased 25% year-over-year and 12% sequentially, with a book-to-bill ratio of 1.11.

Full Year 2025 Revenue: $981 million, marking the highest annual revenue in the company's history.

Adjusted EBITDA: $61 million for Q4, up 17% year-over-year, with a margin of 23.5%.

Adjusted EPS: $0.91 for Q4, a 20% increase year-over-year; full-year adjusted EPS was $3.29, a 7% increase.

Operating Cash Flow: $9 million in Q4, down from $62 million in Q4 2024; full-year cash flow was $64 million.

Gross Margin: 45.5% in Q4, down from 47% in Q4 2024, attributed to higher dual running costs.

2Strategic Updates and Business Highlights

Growth Strategy: Focus on high-growth markets such as AI-driven robotics, minimally invasive surgery, and precision medicine.

Investment in Innovation: Continued investments in next-generation technologies, including robotic surgery and intelligent AI solutions.

Acquisition Pipeline: Raised over $600 million in November 2025, with nearly $1.5 billion in acquisition capacity. The company is actively pursuing mid to larger opportunities in medical technologies and consumables.

Regional Manufacturing Initiative: Transitioning manufacturing closer to customers to enhance supply chain resilience and efficiency.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $1,030 million to $1,050 million, indicating 4% to 6% organic growth.

Q1 2026 Outlook: Anticipated organic growth of 1% to 3% and reported growth of 7% to 9%.

Gross Margin Target for 2026: Expected to increase to approximately 47%, reflecting a 100 basis point improvement.

Adjusted EBITDA for 2026: Projected between $245 million and $250 million, with a margin of around 24%.

Operating Cash Flow Guidance: Expected to rebound to $145 million to $185 million in 2026.

4Bad News, Challenges, or Points of Concern

Margin Compression: Gross margins fell due to prioritizing customer deliveries over manufacturing transfers, leading to higher costs and inventory levels.

Cash Flow Decline: Operating cash flow decreased significantly in Q4 compared to the previous year, impacted by regional manufacturing dynamics and inventory builds.

Dilution from Fundraising: The recent equity fundraise is expected to have a temporary headwind on EPS growth, estimated at $0.22 to $0.24.

5Notable Q&A Insights

Bookings Growth: All business segments reported double-digit bookings growth, indicating strong demand across the board.

Automation Enabling Technologies: Significant momentum in robotics and automation, driven by new product launches and a recovering semiconductor market.

Precision Medicine: The Keyon acquisition is performing better than expected and is contributing to both project-based and recurring revenue streams.

Competitive Positioning: The company maintains a strong position in the market, particularly in precision robotics and AI applications, with ongoing investments in technology leadership. Overall, Novanta Inc. demonstrated strong financial performance in Q4 2025, with a positive outlook for 2026 despite some challenges related to margins and cash flow. The company's strategic investments and acquisition pipeline position it well for future growth.